Blue Owl Capital Holdings LP Adc Therapeutics Sa Transaction History
Blue Owl Capital Holdings LP
- $231 Million
- Q3 2025
A detailed history of Blue Owl Capital Holdings LP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Blue Owl Capital Holdings LP holds 733,568 shares of ADCT stock, worth $2.9 Million. This represents 1.27% of its overall portfolio holdings.
Number of Shares
733,568
Previous 733,568
-0.0%
Holding current value
$2.9 Million
Previous $1.97 Million
49.31%
% of portfolio
1.27%
Previous 1.06%
Shares
1 transactions
Others Institutions Holding ADCT
# of Institutions
111Shares Held
67.9MCall Options Held
39.8KPut Options Held
68.4K-
Redmile Group, LLC San Francisco, CA15.7MShares$62 Million6.9% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.14MShares$32.2 Million0.06% of portfolio
-
Prosight Management, LP Dallas, TX7.47MShares$29.6 Million7.9% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$23.4 Million0.81% of portfolio
-
Morgan Stanley New York, NY3.67MShares$14.5 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $307M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...